Form 4: Amgen EVP Santos Reports Stock Transactions

EVP of Operations at Amgen, Esteban Santos, reports disposition of shares to cover tax obligations and ongoing holdings including restricted stock units and shares in the 401(k) plan.

Summary

• On April 30, 2024, Esteban Santos, EVP of Operations at Amgen, reported a transaction involving common stock.
• Santos disposed of 683 shares of common stock at a price of $276.38 to cover tax obligations.
• Following the transaction, Santos directly owns 69,530 shares of Amgen common stock.
• Santos also indirectly owns 856.6105 shares through the company's 401(k) plan.
• The reported holdings include restricted stock units (RSUs) that will vest at various dates in the future.
• These RSUs include 1,151 RSUs vesting on May 5, 2024, 1,348 RSUs vesting on April 30, 2025, and other RSUs vesting in installments through 2027.
• The holdings also include 660 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan.

Sentiment

Score: 5

Explanation: This Form 4 filing represents routine transactions and holdings, with no indication of unusual activity. The sentiment is neutral.

Positives

• The reporting person continues to hold a significant number of shares in the company, indicating confidence in Amgen's future.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors to gauge sentiment and potential future stock performance.

Comparison to Industry Standards

• Monitoring insider transactions is a common practice in the pharmaceutical industry, with companies like Johnson & Johnson, Pfizer, and Merck also subject to similar reporting requirements.
• The vesting schedules for RSUs are typical for executive compensation packages in large corporations, designed to align management's interests with long-term shareholder value.

Stakeholder Impact

• The filing provides transparency to shareholders regarding insider transactions.
• The transactions are unlikely to have a significant impact on employees, customers, suppliers, or creditors.

Key Dates